A major new advance in the HIV prevention arsenal. We know the preventive treatment for HIV, or Prep for “pre-exposure prophylaxis”, in the form of tablets to be taken frequently. It exists in injectable and long-acting form. In September 2023, the European Medicines Agency granted its marketing authorization in September 2023.
This is cabotegravir, marketed under the name Apretude. In May 2024, the High Authority for Health issued a favorable opinion for its reimbursement. It is now done. Since March 2, this treatment has been available in France and 100% refundable by health insurance in application of a decree of February 26.
Clinical trials have notably shown that this new injectable treatment is more effective than the daily oral regimen. The specialized agency of the United Nations, UNAIDS, welcomed this progress in the fight against HIV, estimating that “This treatment could be a game-changer.”
Yes, we suspect: you have had enough
Seeing these messages calling for donations can be painful. We know it. And we must admit that we would prefer not to have to write them…
But here it is: it is crucial for Humanity. If this title still exists today, it is thanks to regular funding from our readers.
- It is thanks to your support that we can practice our profession with passion. We depend neither on the interests of a billionaire owner nor on political pressure: no one dictates to us what we should say or keep quiet.
- Your commitment also frees us from the race for clicks and audiences. Rather than seeking to capture attention at all costs, we choose to cover the subjects that our editorial staff deems essential : because they deserve to be read, understood, shared. Because we think they will be useful to you
At present, less than a quarter of readers who come to the site more than 3 times per week help us finance our work, through their subscription or through their donations. If you want to protect independent journalism, please join them.
